Workplace bullying negatively impacts employees’ physical and mental health, leading to higher company costs including increased employee illness, use of sick days, and medical costs, ultimately affecting productivity. Studies report that 25-30% of employees experience bullying and emotional abuse sometime during their work life.
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that many adults with a depressive disorder, Bipolar Disorder (BPD), or an anxiety disorder may also have undiagnosed Attention-Deficit/Hyperactivity Disorder (ADHD), according to a longitudinal retrospective medical claims analysis presented today at a major medical meeting of child and adolescent psychiatrists.
Point-of-use water treatment and improved water storage reduced the incidence of diarrhea by 90 percent when compared to improved water storage alone in camps for the internally displaced in Liberia, according to a study by researchers at the Johns Hopkins Bloomberg School of Public Health. In camp settings during emergencies, diarrheal diseases have accounted for more than 40 percent of all deaths, and a majority of deaths of small children. The study evaluated Procter & Gamble’s (NYSE: PG) PUR(R) Purifier of Water and is the first to test the effectiveness of PUR under emergency conditions. It is published in the October 2006 edition of Tropical Medicine and International Health.
IDM Pharma (NASDAQ:IDMI) announced today that the company has submitted an electronic New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Junovan(TM) (mifamurtide for injection), requesting approval for its use in the treatment of newly diagnosed resectable high grade osteosarcoma patients following surgical resection in combination with multiple agent chemotherapy.
Royal Philips (NYSE: PHG, AEX: PHI) announced the availability of triplets monitoring functionality for its industry-leading line of obstetrical care fetal and maternal monitors, Avalon FM20 antepartum and Avalon FM30 intrapartum. Philips is the first company to introduce a fetal monitor that enables non-invasive triplets monitoring with a single device.
Schering-Plough Corporation (NYSE: SGP) reported that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL(R) (posaconazole) Oral Suspension for the treatment of oropharyngeal candidiasis (OPC), including infections refractory to itraconazole and/or fluconazole. OPC is a fungal infection of the mouth and throat caused by the yeast Candida. NOXAFIL is a novel triazole antifungal agent discovered and developed by Schering-Plough Research Institute.
Many people with constipation are confused about the cause of their condition and its appropriate treatment with laxatives. Results of a new large-scale global survey, announced today, show that many people wrongly fear that laxatives are addictive and that their use for long periods of time actually causes constipation.1,2
Poor adherence to medication is a recognized medical problem, costing an estimated $100 billion a year in the United States.(i) New data show that while there is a steady decline in adherence to medications for ulcerative colitis (UC), drug formulation and the number of pills taken each day do not affect long-term adherence. The data were presented today at the annual scientific meeting of the American College of Gastroenterology by University of Chicago researcher Sunanda Kane, M.D.
Believe it or not, the holiday season is just around the corner. Before you know it, the streets will be bustling with shoppers, malls will be donned with holiday decor, and the sounds of the season will be echoing through your ears — bringing with them the anticipation of seeing family and friends once again for a season filled with good times, good memories, and great holiday foods.
Bayer HealthCare (BHC) and Topsun Science and Technology Co., Ltd. (Topsun, 600771.SS) together announced that BHC’s Consumer Care Division has signed an agreement in China to acquire the Western over-the-counter (OTC) cough and cold portfolio of Topsun Science and Technology Qidong Gaitianli Pharmaceutical Co., Ltd. for the consideration of RMB 1,072 million (approximately EUR 103 million) plus contingent payments of RMB 192 million (approximately EUR 19 million) subject to fulfilment of certain performance criteria.